<DOC>
	<DOCNO>NCT00385307</DOCNO>
	<brief_summary>To evaluate efficacy two fixed dos SR58611A ( 175 mg q12 350 mg q12 ) compare placebo patient Major Depressive Disorder ( MDD ) use paroxetine ( 20 mg qd ) positive control . In addition , tolerability safety SR58611A patient MDD evaluate .</brief_summary>
	<brief_title>Efficacy Safety SR58611A Patients With Major Depressive Disorder ( SIRIUS )</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Amibegron</mesh_term>
	<criteria>Patient Major Depressive Disorder diagnose accord Diagnostic Statistical Manual Mental Disorders DSMIVTR Patient meet criterion recurrent Major Depressive Episode ( MDE ) Patient meet severity assessment depression specify study Patient immediate risk suicidal behavior Patient unstable medical condition Patient psychotic feature , catatonic feature , seasonal pattern postpartum onset Patient take concomitant treatment may interfere valid collection interpretation study data Patient treat nonpharmacologic therapy intend treat depression past 6 month Patient treat paroxetine ( Paxil ) within previous 6 month Patient pregnant breastfeeding , likely become pregnant course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Depression</keyword>
	<keyword>Clinical Trials</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>